Infliximab - Axial spondyloarthritis

You are here : Home > Formulary Search > Infliximab - Axial spondyloarthritis

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Red

Formulations :

Intravenous infusion
Subcutaneous injection (sc)

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Associated Icons :

Guidelines

ICB

NICE

SPC

Restrictions / Comments :

Important

For use in ankylosing spondylitis only

Documentation

NICE Technology Appraisal

NICE TA383 - TNF-alpha inhibitors for ankylosing spondylitis and non radiographic axial spondyloarth

Evidence Review

PAD Profile

ChemicalSubstance :

Infliximab

Indication :

Axial spondyloarthritis

Group Name :

Keywords :

Biologic, anti-TNF, biosimilar, cytokine modulator, monoclonal antibody, TNF-alpha, axial spondyloarthritis, AS, ankylosing spondylitis

Brand Names Include :

Remicade, Remsima, Inflectra, Flixabi, Zessly

Important Information :

Latest Additions Date From :

Latest Additions Date To :

Guidelines :

Axial spondyloarthritis

Supporting Documents :

Other Indications

Below are listed other indications that Infliximab is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Axial spondyloarthritis.

Committee Recommendations (4)

05 Feb 25 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed the reviewed and updated axial spondyloarthritis pathway.

Treatment pathway is available on separate guidelines page.

06 Jan 21 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee recommends the use of infliximab subcutaneous injection or infliximab intravenous infusion. Clinicians & patients will be able to choose the most appropriate product for them at the point of prescribing.

08 Jul 19 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

The Medicines and Healthcare Products Regulatory Agency (MHRA) recommends to prescribe biological products by brand name to ensure that substitution of a biosimilar product does not occur when the medicine is dispensed by the pharmacist. Https://www/gov/uk/drug-safety-update/biosimilar-products

Primary care prescriber should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient's medication.

06 Jul 16 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

The PCN agreed the attached Spondyloarthritis biologic treatment pathway in line with TA383 which was published by NICE in February 2016. The PCN previously (May 2015) supported the branded prescribing of biosimilar Infliximab(Inflectra OR Remsima) to be used in all new patients for all indications where they have licensing authorisation in the UK. Switching to Inflectra or Remsima has been discussed locally with acute trusts and specialists.